DOCSLIB.ORG

210311 Wild Guided Report.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
210311 Wild Guided Report.Indd ********** MammakarzinomMammakarzinom DR. SENCKENBERGISCHESDR. SENCKENBERGISCHES PatientPatient name name DiagnosisDiagnosis R PATHOLOGIER PATHOLOGIE PatientPatient 1D 1D Testl234Testl234 ICD-10-CMICD-10-CM code code ;;:;;;:; spsp CaseCase 1D 1D EU001930EU001930 MeSHMeSH ID/term ID/term D001943D001943 (Breast (Breast Neoplasms) Neoplasms) W1ldlabW1ldlab DateDate of birth of birth AdditionalAdditional MeSH MeSH IDs IDs - - SexSex FemaleFemale SampleSample type type FFPEFFPE LabtestLabtest VCF-completeVCF-complete import import (paired) (paired) GeneralGeneral dataset dataset 1D 1D105685598965 105685598965 EthnicityEthnicity EUR EUR TumorTumor cellularity cellularity 100% 100% OrganizationalOrganizational unit unit SIPV2TESTSIPV2TEST CVICVI dataset dataset 1D 1D 105685598965105685598965 CountryCountry DE DE SoftwareSoftwareversionversion 4.3.34.3.3 MutationalMutational status status of commonly of commonly mutated mutated genes genes in the in the patient patient disease disease ATMATM BRCAlBRCAl BRCA2BRCA2 CDK4CDK4 CDKN2ACDKN2A CHEK2CHEK2 EGFREGFR ERBB2ERBB2 ESRlESRl PALB2PALB2 PIK3CAPIK3CA notnot notnot notnot notnot notnot notnot notnot notnot notnot notnot 1 SNV1 SNV identifiedidentified identifiedidentified identifiedidentified identifiedidentified identifiedidentified identifiedidentified identifiedidentified identifiedidentified identifiedidentified identifiedidentified PTENPTEN TP53TP53 notnot notnot identifiedidentified identifiedidentified SUMMARYSUMMARY OverviewOverview of potential of potential treatment treatment impacts impacts OverviewOverview of prognostic of prognostic and and diagnostic diagnostic findings findings ClinicalClinical trials trials found found 3 3Effective Effective 1 1lneffective lneffective o Safetyo Safety O OPrognostic Prognostic O ODiagnostic Diagnostic 6 6Trials Trials VAF/CopyVAF/Copy PotentialPotential impact impact TreatmentTreatment DrugDrug approval approval BiomarkerBiomarker BiomarkerBiomarker score score TrialsTrials NumberNumber AlpelisibAlpelisib ApprovedApproved PIK3CAPIK3CA ClinicallyClinically EffectiveEffective 66.67%66.67% 4 4 FulvestrantFulvestrant ApprovedApproved p.E545Ap.E545A (SNV) (SNV) r;,r;, Approved Approved -- �� PIK3CAPIK3CA EffectiveEffective EverolimusEverolimus Approved*Approved* 66.67%66.67% 2)2) Preclinical Preclinical 2 2 p.E545Ap.E545A (SNV) (SNV) -- PIK3CAPIK3CA EffectiveEffective SirolimusSirolimus OtherOther 66.67%66.67% 2)2) Preclinical Preclinical 0 0 p.E545Ap.E545A (SNV) (SNV) -- PIK3CAPIK3CA lneffectivelneffective TrastuzumabTrastuzumab Approved*Approved* 66.67%66.67% 4)4)ClinicalClinical p.E545Ap.E545A (SNV) (SNV) 1 1 �� * the* the drug drug is approved is approved for forthe the cancer cancer type type but but either either none none of theof the currently currently approved approved biomarkers biomarkers for forthis- this drug- drug were were identified, identified, or anor anapproved approved resistance resistance biomarkerbiomarker for forthe the drug drug was was identified identified in this in this patient. patient. Therefore, Therefore, the the drug drug labe[ labe[ may may not not cover cover the the analyzed analyzed patient; patient; VAF VAF = Variant = Variant allele allele frequency frequency BiomarkerBiomarker score: score: AMP AMP score score and and CVI CVI score. score. Clinically Clinically approved: approved: Approved Approved biomarker biomarker (by (bythe the FDA, FDA, EMA, EMA, or NCCN)or NCCN) to predictto predict a specific a specific effect effectin thein the patient's patient's disease.disease. Clinical: Clinical: Not Not yet yetapproved approved biomarker biomarker for forthe the patient's patient's disease. disease. Observed Observed in clinical in clinical studies studies as aas potential a potential biomarker biomarker to predictto predict a specific a specific effect effectof theof the drug.drug. Preclinical: Preclinical: This This biomarker biomarker has has not not yet yetbeen been observed/tested observed/tested in patients in patients to predict to predict a specific a specific effect effectof theof the drug. drug. lt is lt supported is supported by preclinicalby preclinical evidence evidence or or translationaltranslational data. data. YouYou can can find find more more details details on theon the biomarker biomarkerscorescore (AMP (AMP and and CVI CVI score) score) in the in the glossary. glossary. TheodorTheodor Stern Stern Kai 7, Kai 7, SignedSigned by: by: MolecularMolecular Health Health GmbH GmbH 6059060590 Frankfurt Frankfurt ReportReportdate: date: 08 Mar 08 2021 Mar 202116:5816:58 (UTC+Ol:00) (UTC+Ol:00) Kurfürsten-AnlageKurfürsten-Anlage 21, 21, ReportReportversion: version: 3 3 6911569115 Heidelberg Heidelberg OrderOrder date: date: 08 Mar 08 2021 Mar 2021 Page Page1 of 13 1 of 13 Patient name ***** Diagnosis Mammakarzinom DR. SENCKENBERGISCHESDR. SENCKENBERGISCHES Patient name***** Diagnosis Mammakarzinom R PATHOLOGIER PATHOLOGIE PatientPatient 1D 1D Testl234Testl234 ICD-10-CMICD-10-CM code code ;;:;;;:; spsp CaseCase 1D 1D EU001930EU001930 MeSHMeSH ID/term ID/term D001943D001943 (Breast (Breast Neoplasms) Neoplasms) W1ldlabW1ldlab DateDate of birth of birth AdditionalAdditional MeSH MeSH IDs IDs - - Sex Female Sample type FFPE Labtest VCF-complete import (paired) General dataset 1D 105685598965 BIOMARKEREthnicity EUR DETAILS Tumor cellularity 100% Organizational unit SIPV2TEST CVI dataset 1D 105685598965 Country DE Software version 4.3.3 Mutational status of commonly mutated genes in the patient disease PIK3CA p.E545A (SNV) 1 ATM BRCAl BRCA2 CDK4 CDKN2A CHEK2 EGFR ERBB2 ESRl PALB2 PIK3CA not not not not not not not not not not 1 SNV ••identified identified identified identified identified identified identified identified identified identified PIK3CA is the catalytic subunit of the lipid phosphoinositide-3-kinase (Pl3K) that activates the Pl3K/AKT signaling pathway to promote cell proliferation and survival.PTEN This variantTP53 strongly activates the downstream pathway in preclinical settings. Alpelisib plus fulvestrant is indicated for this variant for the treatment of hormonenot receptor-positive,not H ER2-negative advanced breast cancer. The HER2-positive tumor of a patient with this variant was resistance to trastuzumab. Althoughidentified not specifically identified tested for this mutation, preclinical models with activating variants are sensitive to the mTOR inhibitors everolimus and sirolimus and have reduced sensitivity to trastuzumab. A [arger study showed that HER2-positive patients with an activating PIK3CA mutation had improved progression-free survival with the addition of everolimus to trastuzumab treatment. PubMedSUMMARY 1D 21358673,28382169,27091708,31091374,23092874 Overview of potential treatment impacts Overview of prognostic and diagnostic findings Clinical trials found 3 Effective 1 lneffective o Safety O Prognostic O Diagnostic 6 Trials Potential impact Treatment Drug approval Biomarker score Clinically Effective Alpelisib + Fulvestrant Approved, ApprovedVAF/Copy Potential impact Treatment Drug approval Biomarker Biomarker score r;, ApprovedTrials Number - Effective EverolimusAlpelisib Approved Approved*PIK3CA Clinically2, Preclinical Effective 66.67% 4 Fulvestrant Approved p.E545A (SNV) r;, Approved -� Effective - 2' Preclinical Sirolimus OtherPIK3CA Effective Everolimus Approved* 66.67% 2) Preclinical 2 p.E545A (SNV) - lneffective Trastuzumab Approved* - Clinical PIK3CA Effective Sirolimus Other 66.67% • 2) Preclinical4, 0 p.E545A (SNV) � * the drug is approved for the cancer type but either none of the currently approved biomarkers for this drug were- identified, or an approved resistance biomarker for the drug was identified in this patient. Therefore, the drug labe[ may not cover the analyzed patient.- PIK3CA ) Clinical Biomarkerlneffective score: AMP score andTrastuzumab CVI score. Clinically Approved* approved: Approved biomarker (by the66.67% FDA, EMA, or NCCN) to predict1 a specific4 effectin the patient's p.E545A (SNV) � disease. Clinical: Not yet approved biomarker for the patient's disease. Observed in clinical studies as a potential biomarker to predict a specific effectof the drug.* the Preclinical: drug is approved This biomarker for the has cancer not yettype been but observed/testedeither none of the in patients currently to approved predict a specificbiomarkers effect forof thisthe- drug.drug ltwere is supported identified, by or preclinical an approved evidence resistance or translationalbiomarker data. for the drug was identified in this patient. Therefore, the drug labe[ may not cover the analyzed patient; VAF = Variant allele frequency YouBiomarker can find more score: details AMP on score the biomarker and CVI score.score Clinically (AMP and approved: CVI score) in Approved the glossary. biomarker (by the FDA, EMA, or NCCN) to predict a specific effectin the patient's disease. Clinical: Not yet approved biomarker for the patient's disease. Observed in clinical studies as a potential biomarker to predict a specific effectof the drug. Preclinical: This biomarker has not yet been observed/tested in patients to predict a specific effectof the drug. lt is supported by preclinical evidence or translational data. You can find more details on the biomarker score (AMP and CVI score) in the glossary. TheodorTheodor Stern Stern Kai 7, Kai 7, SignedSigned by: by: MolecularMolecular Health Health GmbH GmbH 6059060590 Frankfurt Frankfurt ReportReportdate: date: 08 Mar 08 2021 Mar 202116:5816:58 (UTC+Ol:00) (UTC+Ol:00) Kurfürsten-AnlageKurfürsten-Anlage 21, 21,
Load more

Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Therapeutic and Prophylactic Use of Oral, Low-Dose Ifns in Species of Veterinary Interest: Back to the Future
    veterinary sciences Review Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future Sara Frazzini 1 , Federica Riva 2,* and Massimo Amadori 3 1 Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy; [email protected] 2 Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, 26900 Lodi, Italy 3 Rete Nazionale di Immunologia Veterinaria, 25125 Brescia, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0250334519 Abstract: Cytokines are important molecules that orchestrate the immune response. Given their role, cytokines have been explored as drugs in immunotherapy in the fight against different pathological conditions such as bacterial and viral infections, autoimmune diseases, transplantation and cancer. One of the problems related to their administration consists in the definition of the correct dose to avoid severe side effects. In the 70s and 80s different studies demonstrated the efficacy of cytokines in veterinary medicine, but soon the investigations were abandoned in favor of more profitable drugs such as antibiotics. Recently, the World Health Organization has deeply discouraged the use of antibiotics in order to reduce the spread of multi-drug resistant microorganisms. In this respect, the use of cytokines to prevent or ameliorate infectious diseases has been highlighted, and several studies show the potential of their use in therapy and prophylaxis also in the veterinary field. In this review we aim to review the principles of cytokine treatments, mainly IFNs, and to update the experiences encountered in animals. Keywords: veterinary immunotherapy; cytokines; IFN; low dose treatment; oral treatment Citation: Frazzini, S.; Riva, F.; Amadori, M.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • Research in Your Backyard Developing Cures, Creating Jobs
    Research in Your Backyard Developing Cures, Creating Jobs PHARMACEUTICAL CLINICAL TRIALS IN ILLINOIS Dots show locations of clinical trials in the state. Executive Summary This report shows that biopharmaceutical research com- Quite often, biopharmaceutical companies hire local panies continue to be vitally important to the economy research institutions to conduct the tests and in Illinois, and patient health in Illinois, despite the recession. they help to bolster local economies in communities all over the state, including Chicago, Decatur, Joliet, Peoria, At a time when the state still faces significant economic Quincy, Rock Island, Rockford and Springfield. challenges, biopharmaceutical research companies are conducting or have conducted more than 4,300 clinical For patients, the trials offer another potential therapeutic trials of new medicines in collaboration with the state’s option. Clinical tests may provide a new avenue of care for clinical research centers, university medical schools and some chronic disease sufferers who are still searching for hospitals. Of the more than 4,300 clinical trials, 2,334 the medicines that are best for them. More than 470 of the target or have targeted the nation’s six most debilitating trials underway in Illinois are still recruiting patients. chronic diseases—asthma, cancer, diabetes, heart dis- ease, mental illnesses and stroke. Participants in clinical trials can: What are Clinical Trials? • Play an active role in their health care. • Gain access to new research treatments before they In the development of new medicines, clinical trials are are widely available. conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug • Obtain expert medical care at leading health care Administration to approve treatments.
    [Show full text]
  • Afelimomab (Rinn) Ic Medicines Under the Following Names: Adonis V
    2248 Supplementary Drugs and Other Substances Adiphenine Hydrochloride (USAN, rINNM) Adrenalone Hydrochloride (pINNM) ⊗ Uses. The use of aesculus has been reviewed;1,2 although there is some evidence suggesting benefit in chronic venous insuffi- Adiphénine, Chlorhydrate d’; Adiphenini Hydrochloridum; Adrénalone, Chlorhydrate d’; Adrenaloni Hydrochloridum; ciency, more rigorous studies are needed.2 Cloridrato de Adifenina; Hidrocloruro de adifenina; NSC- Adrenalonu chlorowodorek; Hidrocloruro de adrenalona. 1. Sirtori CR. Aescin: pharmacology, pharmacokinetics and thera- 129224; Spasmolytine. Адреналона Гидрохлорид peutic profile. Pharmacol Res 2001; 44: 183–93. Адифенина Гидрохлорид C H NO ,HCl = 217.6. 2. Pittler MH, Ernst E. Horse chestnut seed extract for chronic ve- 9 11 3 nous insufficiency. Available in The Cochrane Database of Sys- C20H25NO2,HCl = 347.9. CAS — 62-13-5. tematic Reviews; Issue 1. Chichester: John Wiley; 2006 (ac- CAS — 50-42-0. ATC — A01AD06; B02BC05. cessed 31/03/06). ATC Vet — QA01AD06; QB02BC05. Profile Preparations Adiphenine and adiphenine hydrochloride have been used as Profile Proprietary Preparations (details are given in Part 3) antispasmodics. Adrenalone hydrochloride is used as a local haemostatic and va- Arg.: Grafic Retard; Herbaccion Venotonico; Nadem; Venastat; Venostasin; soconstrictor. It has also been used with adrenaline in eye drops Austria: Aesculaforce; Provenen; Reparil; Venosin; Venostasin; Belg.: Preparations for glaucoma. Reparil; Veinofytol; Venoplant; Braz.: Phytovein; Reparil; Varilise;
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Identification of Compounds That Rescue Otic and Myelination
    RESEARCH ARTICLE Identification of compounds that rescue otic and myelination defects in the zebrafish adgrg6 (gpr126) mutant Elvira Diamantopoulou1†, Sarah Baxendale1†, Antonio de la Vega de Leo´ n2, Anzar Asad1, Celia J Holdsworth1, Leila Abbas1, Valerie J Gillet2, Giselle R Wiggin3, Tanya T Whitfield1* 1Bateson Centre and Department of Biomedical Science, University of Sheffield, Sheffield, United Kingdom; 2Information School, University of Sheffield, Sheffield, United Kingdom; 3Sosei Heptares, Cambridge, United Kingdom Abstract Adgrg6 (Gpr126) is an adhesion class G protein-coupled receptor with a conserved role in myelination of the peripheral nervous system. In the zebrafish, mutation of adgrg6 also results in defects in the inner ear: otic tissue fails to down-regulate versican gene expression and morphogenesis is disrupted. We have designed a whole-animal screen that tests for rescue of both up- and down-regulated gene expression in mutant embryos, together with analysis of weak and strong alleles. From a screen of 3120 structurally diverse compounds, we have identified 68 that reduce versican b expression in the adgrg6 mutant ear, 41 of which also restore myelin basic protein gene expression in Schwann cells of mutant embryos. Nineteen compounds unable to rescue a strong adgrg6 allele provide candidates for molecules that may interact directly with the Adgrg6 receptor. Our pipeline provides a powerful approach for identifying compounds that modulate GPCR activity, with potential impact for future drug design. DOI: https://doi.org/10.7554/eLife.44889.001 *For correspondence: [email protected] †These authors contributed Introduction equally to this work Adgrg6 (Gpr126) is an adhesion (B2) class G protein-coupled receptor (aGPCR) with conserved roles in myelination of the vertebrate peripheral nervous system (PNS) (reviewed in Langenhan et al., Competing interest: See 2016; Patra et al., 2014).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]